C. Sacco

发表

Characterization of overt B-cell lymphomas in patients with hepatitis C virus infection.

D. Sansonno, F. Dammacco, V. Zagonel, 1997, Blood.

Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial

C. Porta, S. Ricci, R. Miceli, 2011, British Journal of Cancer.

The role of eosinophils in the pathobiology of Hodgkin's disease.

A. Carbone, A. Gloghini, A. Pinto, 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

Oral Anticancer Therapy Project: Clinical utility of a specific home care nursing program.

V. Fabbroni, G. Tortora, V. Zagonel, 2019, Journal of clinical nursing.

Quality-of-life analysis of the MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG study comparing platinum-based versus non-platinum-based chemotherapy in patients with partially platinum-sensitive recurrent ovarian cancer

I. Vergote, S. Pignata, J. Bryce, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Randomized Controlled Trial Testing the Efficacy of Platinum-Free Interval Prolongation in Advanced Ovarian Cancer: The MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG Study.

I. Vergote, S. Pignata, J. Bryce, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: results from a large patient cohort.

C. Sternberg, F. Atzori, M. Milella, 2013, European journal of cancer.

Phase II study of irinotecan and docetaxel in patients with previously treated non-small cell lung cancer: an Alpe-Adria Thoracic Oncology Multidisciplinary group study (ATOM 007).

R. Spizzo, G. Fasola, O. Belvedere, 2006, Lung cancer.

Cisplatin and gemcitabine in non-small-cell lung cancer.

C. Sacco, A. Iop, N. Pella, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Expression and prognostic significance of APE1/Ref-1 and NPM1 proteins in high-grade ovarian serous cancer.

C. Vascotto, G. Tell, M. Poletto, 2014, American journal of clinical pathology.

Simplified gemcitabine and platin regimen in patients with advanced or metastatic non-small cell lung cancer (NSCLC) to be proposed as neoadjuvant therapy.

S. Cingarlini, A. Bearz, C. Sacco, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Taxane-induced nail changes: incidence, clinical presentation and outcome.

B. Piraccini, A. Tosti, F. Puglisi, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Dose Finding of Ifosfamide Administered with a Chronic Two-Week Continuous Infusion

A. Bearz, C. Sacco, J. Mantero, 2003, Oncology.

Docetaxel, with or without estramustine phosphate, as first‐line chemotherapy for hormone‐refractory prostate cancer: results of a multicentre, randomized phase II trial

E. Galligioni, G. Cetto, E. Comploj, 2008, BJU international.

High-dose, continuous infusion Interleukin-2 in the treatment of metastatic renal cell carcinoma: Experience of the C.R.O., Aviano

R. Talamini, E. Galligioni, S. Morassut, 1996 .

A randomized, open label, prospective study comparing the association between sorafenib (So) and interleukin-2 (IL-2) versus So alone in advanced untreated renal cell cancer (RCC): Rosorc Trial.

C. Porta, S. Ricci, R. Miceli, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic significance of the detection of tumour cells in peripheral blood stem cell collections in stage II and III breast cancer patients treated with high-dose therapy

R. Fanin, F. Patriarca, C. Sacco, 2003, Bone Marrow Transplantation.

Updated results of INT70/09 phase II study of pazopanib (PZP) monotherapy for patients with relapsed/refractory urothelial cancer (UC).

L. Mariani, C. Morosi, N. Zaffaroni, 2011, Journal of Clinical Oncology.

Hepatitis-C Virus (Hcv)-Associated B-Cell Lymphoproliferative Disorders

D. Sansonno, F. Dammacco, A. Carbone, 1995 .

Acute Myeloid Leukemia following Chronic Low-Dose Cyclophosphamide for Metastatic Breast Cancer

F. Patriarca, C. Sacco, C. Sacco, 2001, Tumori.

Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial.

A. Rossi, C. Gridelli, D. Galetta, 2003, Journal of the National Cancer Institute.

Rearrangements of bcl-6, bcl-2, c-myc and 6q deletion in B-diffuse large-cell lymphoma: clinical relevance in 71 patients.

G. Gaidano, V. Zagonel, G. Saglio, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial.

D. Katsaros, B. Weber, S. Pignata, 2014, The Lancet. Oncology.

Preoperative chemoradiotherapy in cancer of the thoracic esophagus.

S. Fongione, C. Sacco, V. Bresadola, 2003, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

Impact of docetaxel‐based chemotherapy on quality of life of patients with castration‐resistant prostate cancer: results from a prospective phase II randomized trial

E. Galligioni, E. Comploj, C. Sacco, 2011, BJU international.

Synchronous Versus Metachronous Metastatic Disease: Impact of Time to Metastasis on Patient Outcome-Results from the International Metastatic Renal Cell Carcinoma Database Consortium.

C. Porta, T. Choueiri, I. Davis, 2020, European urology oncology.

Early Integration of Palliative Care in Oncology Practice: Results of the Italian Association of Medical Oncology (AIOM) Survey

M. Maltoni, L. Cavanna, V. Zagonel, 2016, Journal of Cancer.

Expression and release of intercellular adhesion molecule‐1 in renal‐cancer patients

Enzo Galligioni, R. Talamini, M. Quaia, 1995, International journal of cancer.

Neo-adjuvant exemestane in elderly patients with breast cancer: a phase II, multicentre, open-label, Italian study.

S. Barni, M. Cazzaniga, C. Sacco, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Prognostic factors in patients receiving third line targeted therapy for metastatic renal cell carcinoma.

Alessio Farcomeni, Valentina Baldazzi, Giuseppe Procopio, 2015, The Journal of urology.

Is It Possible to Improve Prognostic Classification in Patients Affected by Metastatic Renal Cell Carcinoma With an Intermediate or Poor Prognosis?

C. Porta, G. Tortora, F. Atzori, 2018, Clinical genitourinary cancer.

Safety and activity of sunitinib in elderly patients (≥ 70 years) with metastatic renal cell carcinoma: a multicenter study.

V. Zagonel, A. Roma, A. Brunello, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Standard vs adapted sunitinib regimen in elderly patients with metastatic renal cell cancer: results from a large retrospective analysis.

E. Scarpi, D. Amadori, L. Moscetti, 2014, Clinical genitourinary cancer.

Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial.

L. Schwartz, L. Mariani, F. D. De Braud, 2012, The Lancet. Oncology.

Comprehensive analysis of 34 MiT family translocation renal cell carcinomas and review of the literature: investigating prognostic markers and therapy targets.

C. Porta, P. Argani, M. Fiorentino, 2020, Pathology.

Oral Anticancer Therapy Project: Clinical utility of a specific home care nursing program.

G. Tortora, V. Zagonel, G. Tonini, 2016, Journal of clinical nursing.

Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and Bacillus Calmette‐Guèrin: Five‐year results of a prospective randomized study

R. Talamini, M. Quaia, A. Carbone, 1996, Cancer.

Analysis of plasma cytokines and angiogenic factors in patients with pretreated urothelial cancer receiving Pazopanib: the role of circulating interleukin-8 to enhance the prognostic accuracy

L. Schwartz, L. Mariani, F. D. De Braud, 2013, British Journal of Cancer.

The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer.

P. Tagliaferri, B. Kopf, N. Normanno, 2019, Gynecologic oncology.

Reducing chemotherapy-associated toxicity in elderly cancer patients.

V. Zagonel, V. Gattei, C. Sacco, 1996, Cancer treatment reviews.

Intermittent docetaxel chemotherapy as first-line treatment for metastatic castration-resistant prostate cancer patients.

S. Buti, E. Galligioni, G. Facchini, 2015, Future oncology.

Lung cancer in the elderly.

D. Serraino, S. Monfardini, V. Zagonel, 1997, Cancer treatment reviews.

Unplanned presentations of cancer outpatients: a retrospective cohort study

G. Fasola, C. Sacco, G. Aprile, 2013, Supportive Care in Cancer.

Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter Italian lung cancer in the elderly study.

S. Barni, R. Labianca, G. Luporini, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic evaluation in palliative care: final results from a prospective cohort study

G. Fasola, F. Puglisi, M. Isola, 2018, Supportive Care in Cancer.

Recommendations for surveillance and follow-up of men with testicular germ cell tumors: a multidisciplinary consensus conference by the Italian Germ cell cancer Group and the Associazione Italiana di Oncologia Medica.

L. Guerra, G. Banna, C. Spreafico, 2019, Critical reviews in oncology/hematology.

Genitourinary tumors, non-prostate

S. J. Park, I. Tannock, S. Groshen, 2012 .

Position Paper of the Italian Association of Medical Oncology on Early Palliative Care in Oncology Practice (Simultaneous Care)

M. Maltoni, R. Labianca, L. Cavanna, 2017, Tumori.

High-Dose Epirubicin in Locally Advanced Operable Noninflammatory Breast Cancer: A Feasibility Trial

D. Crivellari, E. Galligioni, E. Candiani, 1997, Tumori.

Overall survival for sorafenib plus interleukin-2 compared with sorafenib alone in metastatic renal cell carcinoma (mRCC): final results of the ROSORC trial.

C. Porta, S. Ricci, R. Miceli, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Procopio G,Verzoni E,Bracarda S,Ricci S,Sacco C,Ridolfi L,Porta C,Miceli R,Zilembo N,Bajetta E,Italian Trials in Medical Oncology (ITMO) group Overall survival for sorafenib plus interleukin-2 compared with sorafenib alone in metastatic renal cell carcinoma (mRCC): final results of the ROSORC

C. Porta, S. Ricci, R. Miceli, 2022 .

P84 High dose epirubicin and cyclophosphamide (EC) vs cyclophosphamide, methotrexate, fluorouracil (CMF) as adjuvant chemotherapy in high risk premenopausal breast cancer patients (PTS). A prospective randomized trial

S. Barni, D. Crivellari, E. Galligioni, 1998 .

Safety and activity of sunitinib in elderly patients (≥70 years) with metastatic renal cell carcinoma: a multicenter study.

V. Zagonel, A. Roma, A. Brunello, 2013 .

Randomized Study of Adjuvant Immunotherapy with Autologous Tumor Cells and BCG in Renal Cancer

R. Talamini, M. Quaia, A. Carbone, 1993, Annals of the New York Academy of Sciences.

Second-Line Chemotherapy in Recurrent Clear Cell Ovarian Cancer: Results from the Multicenter Italian Trials in Ovarian Cancer (MITO-9)

D. Katsaros, A. Gadducci, S. Pignata, 2014, Oncology.

Negative prognostic factors and resulting clinical outcome in patients with metastatic renal cell carcinoma included in the Italian nivolumab-expanded access program.

C. Porta, F. di Costanzo, S. Buti, 2018, Future oncology.

A randomized multicenter phase III study comparing weekly versus every 3 weeks carboplatin (C) plus paclitaxel (P) in patients with advanced ovarian cancer (AOC): Multicenter Italian Trials in Ovarian Cancer (MITO-7)-European Network of Gynaecological Oncological Trial Groups (ENGOT-ov-10) and Gynec

D. Katsaros, B. Weber, G. Scambia, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tumor measurements on computed tomographic images of non-small cell lung cancer were similar among cancer professionals from different specialties.

M. Bazzocchi, G. Fasola, O. Belvedere, 2004, Journal of clinical epidemiology.

Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial.

A. Rossi, C. Gridelli, D. Galetta, 2003, Journal of the National Cancer Institute.

Lung cancer in the elderly.

C. Gridelli, D. Serraino, S. Monfardini, 1994, European journal of cancer.

P-29 Phase II study of irinotecan plus docetaxel in previously treated non-small cell lung cancer (NSCLC) patients: preliminary results. An Alpe Adria thoracic oncology multidisciplinary group study (ATOM 007)

R. Spizzo, G. Fasola, O. Belvedere, 2003 .

Adjuvant chemotherapy with high-dose epirubicin and cyclophosphamide vs CMF in high-risk premenopausal breast cancer patients (pts). Prospective randomized phase III trial.

S. Barni, D. Crivellari, E. Galligioni, 1996 .

Progression-free survival (PFS) and overall survival (OS) in patients receiving three targeted therapies (TTs) for metastatic renal cell carcinoma (mRCC).

F. Atzori, L. Cerbone, F. Boccardo, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: results from a large patient cohort.

C. Sternberg, F. Atzori, M. Milella, 2013, European journal of cancer.

Safety and efficacy of atezolizumab (atezo) in patients (pts) with autoimmune disease (AID): Subgroup analysis of the SAUL study in locally advanced/metastatic urinary tract carcinoma

R. Huddart, C. Sternberg, F. Massari, 2019, Annals of Oncology.

Proof of concept of correlation between progression-free survival (PFS) and overall survival (OS) in treatment-naive patients with advanced renal-cell carcinoma (mRCC): Final results of a randomized phase II study comparing sorafenib plus interleukin-2 (IL-2) versus sorafenib alone: The ROSORC trial

C. Porta, S. Ricci, R. Miceli, 2013 .

Overall survival (OS) of sorafenib (So) plus interleukin-2 (IL-2) versus So alone in patients with treatment-naive metastatic renal cell carcinoma (mRCC): Final update of the ROSORC trial.

C. Porta, S. Ricci, R. Miceli, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Subgroup analysis and updated results of the randomized study comparing sorafenib (So) plus interleukin-2 (IL-2) versus So alone as first-line treatment in metastatic renal cell carcinoma (mRCC).

C. Porta, S. Ricci, R. Miceli, 2010 .